查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1968547

Guillain-Barré二氏症候群診斷市場 - 全球產業規模、佔有率、趨勢、機會、預測：按檢測方法、最終用途、地區和競爭對手分類，2021-2031年

Guillain-Barre Syndrome Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test, By End-use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球Guillain-Barré二氏症候群診斷市場預計將從 2025 年的 1.6101 億美元成長到 2031 年的 1.8552 億美元，複合年成長率為 2.39%。

該市場涵蓋了用於識別這種影響周邊神經系統的急性自體免疫疾病所需的專業醫學調查方法，例如腦脊髓液分析、肌電圖和神經傳導研究。推動該市場成長的關鍵因素包括茲卡病毒和曲狀桿菌菌等領先感染在全球範圍內的感染疾病率不斷上升，以及易患自體免疫併發症的老齡人口不斷成長。此外，早期療育對於預防永久性神經損傷的重要性日益凸顯，也顯著推動了全球對精準診斷解決方案的需求成長。

市場概覽
預測期 2027-2031
市場規模：2025年 161,010,000 美元
市場規模：2031年 1.8552億美元
複合年成長率：2026-2031年 2.39%
成長最快的細分市場 腰椎穿刺
最大的市場 北美洲

儘管有這種需求，但由於神經系統專科手術高成本以及發展中地區缺乏熟練的專業人員等因素，市場面臨許多障礙。這些因素常常導致誤診，而診斷差距加劇了疾病帶來的社會經濟負擔。例如，根據格林-Guillain-Barré二氏症候群患者的就業狀況因疾病而發生變化，這凸顯了診斷延遲或不準確對患者生活和醫療保健系統造成的嚴重長期影響。

市場促進因素

與Guillain-Barré二氏症候群)相關的感染疾病不斷增加，是推動市場擴張的主要因素。隨著病毒病原體和病毒感染後併發症引發自體免疫反應的病例增多，臨床上對利用肌電圖和腰椎穿刺進行快速鑑別診斷的需求日益成長。免疫因素與神經系統預後之間的相關性對於滿足此診斷需求至關重要，因為臨床醫生需要將 GBS 與其他神經病變分開來，以便啟動適當的治療。例如，感染疾病研究與政策中心在 2024 年 2 月發布的報告《顧問討論呼吸道合胞病毒疫苗接種後的格林-巴利病例》中指出，聯邦衛生部門審查了 23 例在呼吸道融合細胞病毒疫苗接種後確診的格林-巴利病例，強調需要加強診斷警惕性以排除其他病因。

同時，基於新型生物標記的診斷測試的開發正在透過實現精準醫療和提高預後準確性來變革該領域。這些先進的測試使臨床醫生能夠更好地對患者進行分類，從而為新興的補體抑制療法做好準備，減少對排除性診斷的依賴，並提高康復率。 Annexon Biosciences 在 2024 年 6 月發布的新聞稿中證實了這種方法的有效性，該新聞稿介紹了一項 III 期臨床試驗，試驗中，根據特定補體基準值進行治療的患者，其緩解率比安慰劑組提高了 2.4 倍。這些臨床成功正在推動對診斷生態系統的更廣泛投資，Annexon Biosciences 在 2024 年籌集了 1.25 億美元的資金，用於支持這些神經系統診斷和治療創新成果的商業化，證明了這一點。

市場挑戰

高成本，加上發展中地區熟練專科醫生的短缺，為全球Guillain-Barré二氏症候群診斷市場帶來了重大挑戰。肌電圖和神經傳導檢查等先進診斷技術需要昂貴的醫療設備和訓練有素、能夠準確解讀複雜數據的神經科。在許多新興經濟體，醫療機構往往缺乏投資這些技術或維持專業人員所需的預算，導致診斷基礎設施有顯著差異。這阻礙了這些檢測方案的廣泛應用，並限制了市場向未開發地區的拓展。

此外，個人所承擔的經濟負擔直接抑制了對診斷服務的需求。當患者面臨高昂的檢測費用時，他們往往會延遲或避免就醫，導致檢測數量減少，診斷機構的收入下降。近期疾病相關自付費用的數據也印證了這項經濟負擔。根據格林巴利症候群/慢性發炎性脫髓鞘多發性神經病變基金會（GBS/CIDP Foundation International）預測，到2025年，約有20%的患者每年將面臨超過5,000美元的自付費用。如此沉重的經濟負擔阻礙了早期準確診斷，減緩了市場發展勢頭，並阻礙了全球先進診斷工具的普及應用。

市場趨勢

將人工智慧 (AI) 應用於神經傳導分析，透過自動化分析複雜的肌電圖波形，正在革新格林巴利症候群 (GBS) 的診斷。這種整合消除了報告中的差異，並提高了對疾病早期階段特徵性細微去髓鞘化模式的檢測準確性。以色列理工學院 (Technion Israel Institute of Technology) 於 2025 年 6 月發表的題為《主導智慧體的 AI 神經傳導研究和肌電圖解讀與報告》的報告重點強調了這些系統的臨床有效性。該報告詳細介紹了一個多智慧體 AI 框架，該框架在檢測異常方面實現了 92.2% 的診斷準確率。這種自動化準確率對於在神經專科人才匱乏的地區實現診斷標準的標準化至關重要。

此外，將高解析度超音波整合到診斷通訊協定中，建立了一種與電生理檢查互補的非侵入性方法。該技術能夠可視化形態學變化，例如面積增大，這些變化通常可作為電生理異常的領先指標。透過識別神經根腫脹，超音波有助於鑑別格林-巴利症候群（GBS）和慢性發炎性脫髓鞘性多發性神經病變。近期證據支持了這個效用。根據美國國立衛生研究院（NIH）於2025年8月發表的題為「Guillain-Barré二氏症候群周圍神經大小的超音波評估」的報告，超音波影像顯示患者組腓總神經存在顯著肥大，與對照組相比平均差異為2.09，表明結構成像提供了一種明確的生物標記，可作為功能性神經傳導數據的補充。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：Guillain-Barré二氏症候群診斷的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依檢查類型（腰椎穿刺、肌電圖等）
    • 按應用領域（醫院/診所、診斷檢查室、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美Guillain-Barré二氏症候群診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲Guillain-Barré二氏症候群診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區Guillain-Barré二氏症候群診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東與非洲Guillain-Barré二氏症候群診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲Guillain-Barré二氏症候群診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球Guillain-Barré二氏症候群診斷市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Cadwell Industries, Inc
  • Natus Medical Incorporated
  • Nihon Kohden Corporation
  • Medtronic plc
  • Bionen srl
  • Deymed Diagnostic sro
  • Neurosoft Ivanovo, Russia
  • Alpine Biomedicals Pvt Ltd.
  • EMS Handels Gesellschaft mbH
  • Rochester Electro-Medical, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 27713

The Global Guillain-Barre Syndrome Diagnostics Market is projected to expand from USD 161.01 Million in 2025 to USD 185.52 Million by 2031, registering a CAGR of 2.39%. This market involves specialized medical testing methodologies, such as cerebrospinal fluid analysis, electromyography, and nerve conduction studies, which are essential for identifying this acute autoimmune disorder impacting the peripheral nervous system. The primary drivers fueling this growth include the increasing global incidence of antecedent infections, such as the Zika virus and Campylobacter jejuni, as well as an aging population that is more prone to autoimmune complications. Additionally, the critical need for early intervention to prevent permanent nerve damage is significantly boosting the demand for precise diagnostic solutions worldwide.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 161.01 Million
Market Size 2031USD 185.52 Million
CAGR 2026-20312.39%
Fastest Growing SegmentLumbar Puncture
Largest MarketNorth America

Despite this demand, the market faces a substantial obstacle due to the high cost of specialized neurological procedures and a shortage of skilled professionals in developing regions, factors that frequently lead to misdiagnosis. This diagnostic gap exacerbates the socioeconomic burden of the disease. For instance, data from the GBS/CIDP Foundation International in 2024 indicated that 41% of Guillain-Barre Syndrome patients underwent employment changes as a result of the condition, highlighting the severe long-term consequences that delayed or inaccurate diagnosis can have on patient livelihoods and healthcare systems.

Market Driver

The rising prevalence of infectious diseases associated with the onset of Guillain-Barre Syndrome acts as a major catalyst for market expansion. As viral pathogens and post-viral complications increasingly trigger autoimmune responses, there is an intensified clinical need for rapid differential diagnosis using electromyography and lumbar puncture. This connection between immune triggers and neurological outcomes is vital for validating diagnostic demand, as clinicians must distinguish GBS from other neuropathies to begin timely treatment. For example, in a February 2024 report titled 'Advisers discuss GBS cases after RSV vaccines,' the Center for Infectious Disease Research and Policy noted that federal health officials reviewed 23 verified cases of Guillain-Barre Syndrome following respiratory syncytial virus vaccinations, emphasizing the need for heightened diagnostic vigilance to rule out other causes.

Simultaneously, the development of novel biomarker-based diagnostic assays is transforming the sector by enabling precision medicine and enhancing prognostic accuracy. These advanced testing methods allow clinicians to better categorize patients for emerging complement-inhibitor therapies, thereby reducing reliance on exclusion-based diagnosis and improving recovery rates. The effectiveness of this approach was demonstrated in a June 2024 press release by Annexon Biosciences regarding their Phase 3 Trial, where patients treated based on specific complement benchmarks showed a 2.4-fold improvement in remission outcomes compared to a placebo. Such clinical success is driving broader investment in the diagnostic ecosystem, as evidenced by Annexon Biosciences raising $125 million in 2024 to support the commercial rollout of these neuro-diagnostic and therapeutic innovations.

Market Challenge

The high cost of specialized neurological procedures combined with the scarcity of skilled professionals in developing regions presents significant barriers to the growth of the Global Guillain-Barre Syndrome Diagnostics Market. Advanced diagnostic techniques, such as electromyography and nerve conduction studies, require expensive medical equipment and highly trained neurologists to accurately interpret complex data. In many emerging economies, healthcare institutions often lack the capital to invest in such technologies or the budget to retain specialized staff, creating a substantial gap in diagnostic infrastructure that prevents the widespread adoption of these testing solutions and limits market expansion into untapped geographical regions.

Moreover, the economic burden placed on individuals directly suppresses the demand for diagnostic services. When patients face prohibitive costs for testing, they often delay or avoid seeking medical attention, resulting in lower testing volumes and reduced revenue for diagnostic providers. This financial strain is evident in recent data concerning the personal costs associated with the condition; according to the GBS/CIDP Foundation International, in 2025, nearly 20% of patients reported facing annual out-of-pocket costs exceeding $5,000. This high financial liability discourages early and accurate diagnosis, thereby stalling market momentum and hindering the overall global adoption of precise diagnostic tools.

Market Trends

The adoption of Artificial Intelligence for Nerve Conduction Analysis is transforming GBS diagnostics by automating the analysis of complex electromyography waveforms. This integration resolves variability in reporting and improves the detection of subtle demyelinating patterns that characterize the early stages of the disease. The clinical validity of these systems was highlighted in a June 2025 report by the Technion Israel Institute of Technology titled 'Agent-guided AI-powered interpretation and reporting of nerve conduction studies and EMG,' which detailed a multi-agent AI framework achieving a diagnostic accuracy of 92.2% for detecting abnormal tests. Such automated precision is essential for standardizing diagnostic criteria across regions where specialized neurological expertise is limited.

Furthermore, the integration of High-Resolution Nerve Ultrasound into diagnostic protocols is establishing a non-invasive supplement to electrophysiology. This modality allows practitioners to visualize morphological changes, such as cross-sectional area enlargement, which often precede electrophysiological abnormalities. By identifying nerve root swelling, ultrasound assists in distinguishing GBS from mimicking neuropathies like CIDP. This utility is supported by recent evidence; according to an August 2025 report by the National Institutes of Health titled 'Ultrasound assessment of peripheral nerve size in Guillain-Barre syndrome,' ultrasound imaging revealed significant peroneal nerve enlargement in patients with a Mean Difference of 2.09 compared to controls, proving that structural imaging provides a confirmatory biomarker that complements functional nerve conduction data.

Key Market Players

  • Cadwell Industries, Inc
  • Natus Medical Incorporated
  • Nihon Kohden Corporation
  • Medtronic plc
  • Bionen s.r.l.
  • Deymed Diagnostic s.r.o.
  • Neurosoft Ivanovo, Russia
  • Alpine Biomedicals Pvt Ltd.
  • EMS Handels Gesellschaft m.b.H.
  • Rochester Electro-Medical, Inc.

Report Scope

In this report, the Global Guillain-Barre Syndrome Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Guillain-Barre Syndrome Diagnostics Market, By Test

  • Lumbar Puncture
  • Electromyography
  • Others

Guillain-Barre Syndrome Diagnostics Market, By End-use

  • Hospitals And Clinics
  • Diagnostic Laboratories
  • Others

Guillain-Barre Syndrome Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Guillain-Barre Syndrome Diagnostics Market.

Available Customizations:

Global Guillain-Barre Syndrome Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Guillain-Barre Syndrome Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test (Lumbar Puncture, Electromyography, Others)
    • 5.2.2. By End-use (Hospitals And Clinics, Diagnostic Laboratories, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Guillain-Barre Syndrome Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test
    • 6.2.2. By End-use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Guillain-Barre Syndrome Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test
        • 6.3.1.2.2. By End-use
    • 6.3.2. Canada Guillain-Barre Syndrome Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test
        • 6.3.2.2.2. By End-use
    • 6.3.3. Mexico Guillain-Barre Syndrome Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test
        • 6.3.3.2.2. By End-use

7. Europe Guillain-Barre Syndrome Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test
    • 7.2.2. By End-use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Guillain-Barre Syndrome Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test
        • 7.3.1.2.2. By End-use
    • 7.3.2. France Guillain-Barre Syndrome Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test
        • 7.3.2.2.2. By End-use
    • 7.3.3. United Kingdom Guillain-Barre Syndrome Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Test
        • 7.3.3.2.2. By End-use
    • 7.3.4. Italy Guillain-Barre Syndrome Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test
        • 7.3.4.2.2. By End-use
    • 7.3.5. Spain Guillain-Barre Syndrome Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test
        • 7.3.5.2.2. By End-use

8. Asia Pacific Guillain-Barre Syndrome Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test
    • 8.2.2. By End-use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Guillain-Barre Syndrome Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test
        • 8.3.1.2.2. By End-use
    • 8.3.2. India Guillain-Barre Syndrome Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test
        • 8.3.2.2.2. By End-use
    • 8.3.3. Japan Guillain-Barre Syndrome Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test
        • 8.3.3.2.2. By End-use
    • 8.3.4. South Korea Guillain-Barre Syndrome Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test
        • 8.3.4.2.2. By End-use
    • 8.3.5. Australia Guillain-Barre Syndrome Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test
        • 8.3.5.2.2. By End-use

9. Middle East & Africa Guillain-Barre Syndrome Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test
    • 9.2.2. By End-use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Guillain-Barre Syndrome Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test
        • 9.3.1.2.2. By End-use
    • 9.3.2. UAE Guillain-Barre Syndrome Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test
        • 9.3.2.2.2. By End-use
    • 9.3.3. South Africa Guillain-Barre Syndrome Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test
        • 9.3.3.2.2. By End-use

10. South America Guillain-Barre Syndrome Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test
    • 10.2.2. By End-use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Guillain-Barre Syndrome Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test
        • 10.3.1.2.2. By End-use
    • 10.3.2. Colombia Guillain-Barre Syndrome Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test
        • 10.3.2.2.2. By End-use
    • 10.3.3. Argentina Guillain-Barre Syndrome Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test
        • 10.3.3.2.2. By End-use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Guillain-Barre Syndrome Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Cadwell Industries, Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Natus Medical Incorporated
  • 15.3. Nihon Kohden Corporation
  • 15.4. Medtronic plc
  • 15.5. Bionen s.r.l.
  • 15.6. Deymed Diagnostic s.r.o.
  • 15.7. Neurosoft Ivanovo, Russia
  • 15.8. Alpine Biomedicals Pvt Ltd.
  • 15.9. EMS Handels Gesellschaft m.b.H.
  • 15.10. Rochester Electro-Medical, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer